# Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

> **NCT03571204** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 27 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** 3BNC117 and 10-1074
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03571204
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-10
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-03-29
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Coronavirus 2019 (COVID-19) pandemic
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571204, "Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03571204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*